No abstract

SCLC developing in association with adenocarcinoma, either synchronously or metachronously, seem linked to EGFR mutation, regardless of TKI use. Our findings suggest that such associated cases should be tested for EGFR mutations.

These results provide evidence that PLC-PDX preclinical platform can strongly contribute to accelerate the identification and diversification of anticancer treatment for aggressive subtypes of pediatric liver cancer. (Hepatology 2016;64:1121-1135).

BACKGROUND:Solitary fi brous tumors of the pleura (SFTPs) are infrequent neoplasms with no standardized criteria to predict risk of recurrence aft er curative surgery. Th e aim of the present study is to validate a recently proposed recurrence score in a large European cohort of patients with SFTP.

No abstract